Bill116th CongressFiled Sep 18, 2020Health
H.Res. 1125
Expressing support for prioritizing racial and ethnic diversity in clinical trials for therapies, diagnostics, and vaccines for COVID-19.
Bill journey · stage 2 of 5
Under committee review
FiledFiled
CommitteeComm.
PassedFloor
Both ChambersBoth
Became LawLaw
What it doesSummary introduced in house (Sep 18, 2020)
This resolution expresses the sense of the House of Representatives that federal agencies should take appropriate actions to (1) ensure meaningful engagement of communities of color in the conduct of COVID-19 (i.e., coronavirus disease 2019) research and participation in clinical trials, and (2) improve equitable access to safe and effective vaccines.
What just happenedSep 18, 2020
Referred to the House Committee on Energy and Commerce.
Who’s behind it
Rep. Engel, Eliot L. [D-NY-16](D-NY)Sponsor
22 cosponsors22 D
22cosponsors1committees3actions11subjects
- Introduced in HouseSep 18, 2020
- Sep 18, 2020IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Sep 18, 2020IntroReferralIntro-H
Introduced in House
- Sep 18, 2020IntroReferral1000
Introduced in House